SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

27 May 2025 Evaluate
A fair growth of 16.39% in the revenue at Rs. 1841.09 millions was reported in the March 2025 quarter as compared to Rs. 1581.80 millions during year-ago period.A good growth in profit of 36.42% reported to Rs. 503.82  millions over Rs. 369.32 millions of corresponding previous quarter.Operating profit for the quarter ended March 2025 rose to 705.60 millions as compared to 576.90 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1841.09 1581.80 16.39 6964.85 5703.40 22.12 6964.85 5703.40 22.12
Other Income 29.75 21.85 36.16 98.15 106.35 -7.71 98.15 106.35 -7.71
PBIDT 705.60 576.90 22.31 2706.11 1836.10 47.38 2706.11 1836.10 47.38
Interest 4.17 6.01 -30.62 16.86 21.10 -20.09 16.86 21.10 -20.09
PBDT 701.43 570.89 22.87 2689.25 1815.00 48.17 2689.25 1815.00 48.17
Depreciation 60.81 39.14 55.37 204.44 158.11 29.30 204.44 158.11 29.30
PBT 640.62 531.75 20.47 2484.81 1656.89 49.97 2484.81 1656.89 49.97
TAX 136.80 162.43 -15.78 605.23 465.76 29.94 605.23 465.76 29.94
Deferred Tax 9.08 72.99 -87.56 38.66 94.76 -59.20 38.66 94.76 -59.20
PAT 503.82 369.32 36.42 1879.58 1191.13 57.80 1879.58 1191.13 57.80
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 38.33 36.47 5.08 38.85 32.19 20.69 38.85 32.19 20.69

Supriya Lifescience Share Price

636.20 -1.75 (-0.27%)
13-Apr-2026 14:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.35
Dr. Reddys Lab 1230.35
Cipla 1211.55
Zydus Lifesciences 923.50
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×